Investigators reported that 322 of 418 women admitted for delivery had anti-HBs levels consistent with protection (77.0%; 95% CI 72.8–80.8). They measured antibody levels using an electrochemiluminescence immunoassay and applied the standard threshold of ≥10 mIU/mL to define seroprotection. The cohort-level result was simple but clinically meaningful: three in four women reached delivery with measurable protective antibody.
The authors noted that the rapid HBsAg screen identified 21 women (5.0%) as positive, though they cautioned that discordant serological patterns suggested some of these might be false positives. The study team therefore reported both antibody-based protection and rapid-test antigen detection to give a fuller picture of maternal hepatitis B status at the time of delivery.
The study found clear differences by timing of vaccination. Two hundred sixty-four women (63.2%) reported receiving at least one vaccine dose. Among those, 203 were vaccinated during the current pregnancy while 61 had been vaccinated before the current pregnancy only. The prevalence of protective anti-HBs varied sharply: 50.6% among never-vaccinated women, 82.0% among those vaccinated before the current pregnancy only, and 95.6% among women vaccinated during pregnancy.
After adjustment for measured covariates, the authors reported that vaccination before the current pregnancy only was associated with higher prevalence of protective antibody (adjusted prevalence ratio 1.54; 95% CI 1.24–1.89) and vaccination during pregnancy had an even larger association (adjusted prevalence ratio 1.86; 95% CI 1.57–2.20). The study team observed that no socio-demographic or behavioural factor retained an independent association with protection in multivariable models.
The authors screened additional HBV markers with a rapid test and described discordant patterns between antigen detection and antibody results. They reported possible false positives among the 21 HBsAg-positive rapid tests because some women with positive rapid antigen tests did not show expected serological profiles on laboratory-based assays. The study did not provide confirmatory molecular testing results in the preprint, and the authors noted the potential for rapid-test misclassification.
This mix of findings—high overall anti-HBs prevalence with a small proportion of rapid-test HBsAg positives and discordant marker patterns—led the investigators to describe the serostatus landscape at delivery as heterogeneous and partly driven by prior vaccination history.
Authors noted programmatic gaps that left women susceptible at delivery. Eighty-two women (19.6%) had neither serological evidence of immunity nor markers of infection; 65 of these had never been vaccinated. The cohort included 300 women who reported a previous negative HBV test; among those, 50 (16.7%) had never been vaccinated despite the negative result.
Completion of the vaccine series was another gap. Of 250 vaccinated women with known completion status, 68 (27.2%) had not completed the recommended three doses. The dominant reasons given were not being told to return for further doses or forgetting. The investigators concluded that a common missed step was failing to convert a negative antenatal test into a clinical action—namely, offering and completing vaccination.
The authors suggested, based on observed frequencies in their sample, that linking every negative antenatal HBV test to a clear vaccination pathway could close much of the identified immunity gap. The preprint did not, however, report an operational model for how that linkage would be implemented.
The authors declared ethics approvals and that vaccination was not provided within the study protocol; infected women were to be referred for care. They acknowledged discordance between rapid-test HBsAg results and laboratory serology, and they did not report confirmatory nucleic acid testing in the preprint. The study also relied on self-reported vaccination histories and completion status for many participants, which the investigators noted could introduce recall bias.
Unanswered questions the authors left in the text include the extent to which rapid-test false positives affected prevalence estimates and how programmatic changes—such as routine offer of vaccination after a negative antenatal test—would perform in practice. The preprint did not provide implementation details or confirmatory testing data to resolve these uncertainties.